Dicoferin — Competitive Intelligence Brief

Dicoferin (NIFUROXAZIDE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nifuroxazide. Area: Other.

phase 3 nifuroxazide Signal transducer and activator of transcription 3 Other Small molecule

Target snapshot

Dicoferin (NIFUROXAZIDE). Dicoferin works by inhibiting the activity of STAT3, a protein involved in cell signaling and inflammation.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dicoferin TARGET	NIFUROXAZIDE		phase 3	nifuroxazide	Signal transducer and activator of transcription 3
Digicor	DIGITOXIN	Eli Lilly	marketed	digitoxin	Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1	1982-01-01
Lanoxin	digoxin	Generic (originally Burroughs Wellcome/GSK)	marketed	Cardiac Glycoside [EPC]	Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2	1954-01-01
Bisabolol	LEVOMENOL		marketed	levomenol	Neuronal acetylcholine receptor subunit alpha-7, Signal transducer and activator of transcription 3
Uabaina	ouabain		marketed	ouabain	Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nifuroxazide class)

1. · 1 drug in this class